Pharma Stocks
-
Bristol Myers Squibb: Value Stock Analysis for Dividend Investors in 2026 – News and Statistics
Apr 14, 2026 The pharmaceutical industry is often viewed as a high-growth yet risky sector, but some companies within it…
Read More » -
Is U.S. market growth strong enough to unloc
Sun Pharma’s expanding U.S. specialty drug portfolio positions it for higher-margin growth amid supply chain shifts. For investors in the…
Read More » -
How Investors Are Reacting To Roche Holding (SWX:ROG) CE Mark For Elecsys NfL MS Blood Test
In early April 2026, Roche announced that its Elecsys Neurofilament Light Chain (NfL) blood test received CE mark approval for…
Read More » -
Is its oncology dominance strong enough to unl
As China’s leading innovative drug developer, Jiangsu Hengrui excels in oncology and beyond, but can its R&D firepower sustain growth…
Read More » -
Is It Too Late To Consider Phibro Animal Health (PAHC) After Its 235% One-Year Surge?
If you are wondering whether Phibro Animal Health’s share price still makes sense after a big run, this article walks…
Read More » -
Is its CDMO dominance strong enough to unlock new ups
As a leading contract development and manufacturing organization, Samsung Biologics drives growth through global biopharma partnerships that matter to your…
Read More » -
Stocks to Watch for April13: Muthoot Finance, Mahindra & Mahindra, Torrent Pharma and more
From Muthoot Finance approving ₹30 interim dividend to Mahindra & Mahindra reporting higher March 2026 production and sales, here are…
Read More » -
Is It Too Late To Consider Jazz Pharmaceuticals (JAZZ) After A 93% One Year Rally?
If you are wondering whether Jazz Pharmaceuticals at around US$194.20 is still offering value after a strong run, the key…
Read More » -
Is Leqembi success strong enough to unlock new upside?
Eisai’s Alzheimer’s breakthrough Leqembi offers U.S. investors exposure to a massive unmet need in neurology. With Biogen partnership driving global…
Read More » -
Is Leqembi success strong enough to unlock new upside?
Eisai’s Alzheimer’s breakthrough Leqembi offers U.S. investors exposure to a massive unmet need in neurology. With Biogen partnership driving global…
Read More »